Results 1 to 10 of about 2,782 (157)

Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases

Molecular Metabolism, 2021
Background: Therapies for metabolic diseases are numerous, yet improving insulin sensitivity beyond that induced by weight loss remains challenging. Therefore, search continues for novel treatment candidates that can stimulate insulin sensitivity and ...
Nina Sonne, Morten A. Karsdal, Kim Henriksen   +2 more
doaj   +5 more sources

Amylin Revisited: A 5-Year Perspective on Its Emerging Role in the Treatment of Diabesity [PDF]

Journal of Obesity & Metabolic Syndrome
Amylin is a pancreatic peptide hormone that regulates blood glucose levels and appetite. This review outlines the physiological role of amylin and highlights recent clinical studies exploring its therapeutic potential in diabetes and obesity.
Chae Won Chung, Jaetaek Kim
doaj   +2 more sources

Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies [PDF]

Metabolism Open
Obesity affects over 2 billion adults globally, with projections indicating that nearly two-thirds of adults will be affected by 2050. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed obesity treatment, achieving weight loss ...
Ioannis G. Lempesis, Maria Dalamaga
doaj   +2 more sources

Novel Amylin‐Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta‐Analysis [PDF]

Endocrinology, Diabetes & Metabolism
Background Long‐acting amylin‐based therapies (ABTs) are emerging anti‐obesity agents; we sought to compare their effects on weight and anthropometric outcomes in adults with overweight/obesity without diabetes, evaluate gastrointestinal (GI) safety, and
A. B. M. Kamrul‐Hasan, Ibrahim Khalil, Kunal Mahajan, Deep Dutta, Mainak Banerjee, Joseph M. Pappachan   +5 more
doaj   +2 more sources

Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders [PDF]

Clinical and Molecular Hepatology
Obesity and its related metabolic comorbidities, including type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, and cardiovascular disease, are increasingly recognized as heterogeneous and multisystemic disorders.
Yun Kyung Cho, Chang Hee Jung
doaj   +2 more sources

Incretin-Related Pathology and Serum Exosome Detection in Experimental Alcohol-Related Brain Damage [PDF]

Biomolecules
Alcohol’s chronic neurotoxic and degenerative effects mediate alcohol-related brain damage (ARBD), which is marked by neurobehavioral, cognitive, and motor deficits.
Suzanne M. de la Monte, Ming Tong, Yiwen Yang   +2 more
doaj   +2 more sources

Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3Research in context [PDF]

EBioMedicine
Summary: Background: Amylin (AmyR) and calcitonin (CTR) receptor co-agonists are currently in Phase II/III clinical trials for obesity treatment. Amylin binds to a heterodimeric receptor composed of CTR and the receptor activity modifying proteins 1, 2 ...
Alexandra Oliveira Carvas, Andrea Leuthardt, Patricia Kulka, Greta Lommi, Shad Hassan, Bernd Coester, Sofia Lundh, Tune Pers, Anna Secher, Kirsten Raun, Thomas A. Lutz, Christelle Le Foll   +11 more
doaj   +2 more sources

Mitochondrial Adaptations in Skeletal Muscle Following Incretin‐Based Therapies: In Vitro [PDF]

Journal of Cachexia, Sarcopenia and Muscle
Background Incretin‐based therapies such as glucagon‐like peptide‐1 receptor agonists (GLP‐1Ras), dual GLP‐1/GIP agonists and amylin analogues have demonstrated significant weight loss benefits.
Victoria Old, Melanie Davies, Matthew Denniff, Pratik Choudhary, Nicholas Eastley, Robert U. Ashford, Emma Watson   +6 more
doaj   +2 more sources

Pharmacologic Disruption: How Emerging Weight Loss Therapies Are Challenging Bariatric Surgery Guidelines [PDF]

Medicina
Obesity is a chronic, relapsing disease with multifactorial origins and significant global health implications. Historically, bariatric surgery has been the most effective intervention for achieving sustained weight loss and metabolic improvement ...
Safi G. Alqatari, Abrar J. Alwaheed, Manal A. Hasan, Reem J. Al Argan, Marj M. Alabdullah, Mohammed D. Al Shubbar   +5 more
doaj   +2 more sources

Pharmacotherapy for Obesity: Recent Updates [PDF]

Clinical Pharmacology: Advances and Applications
Thomas Ward Fredrick, Michael Camilleri, Andres Acosta Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, 55905, USACorrespondence: Michael Camilleri, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, 55905 ...
Fredrick TW, Camilleri M, Acosta A
doaj   +2 more sources